Skip to content
MARKETS / NYSE / INFU
NYSE · SURGICAL & MEDICAL INSTRUMENTS & APPARATUS · MID CAP

InfuSystem Holdings, Inc. INFU

17 fiscal years on record · USD · FY2025 reported · SEC filings only
$143.4M
▲ 6.4% YoY
$6.6M
▲ 182.6% YoY
$23.8M
▲ 23.1% YoY
In brief

What this company does

It provides its products and services to hospitals, oncology practices, ambulatory surgery centers, and other alternate site healthcare providers. Its headquarters is in Rochester Hills, Michigan, and it operates its business from a total of seven locations in the United States and Canada. As of December 31, 2025, it had 473 employees, including 461 full-time employees and 12 part-time or contract employees. As of December 31, 2025, it had contracts with nearly 840 third-party payer networks. It provides its services under a two-platform model: Patient Services and Device Solutions. Patient Services provides turnkey solutions designed to be implemented without service disruptions, allowing its healthcare provider customers to focus on practicing medicine. Its Device Solutions segment sells or rents new and pre-owned pole-mounted and ambulatory infusion pumps and other Durable Medical Equipment, sells treatment-related consumables, and provides biomedical recertification, maintenance and repair services for oncology practices and other healthcare site settings. InfuSystem Holdings, Inc. is a Delaware corporation, formed in 2005, that operates through its subsidiary InfuSystem, Inc., a Delaware corporation.

Written from the business description in InfuSystem Holdings, Inc.'s annual report to the U.S. Securities and Exchange Commission, filed 27 February 2026. Every sentence was checked against that document before publication.

Growth
USD 143.4M
Revenue, FY2025 · full 17-year series below
Revenue $M Net income $M
FY2025 · Revenue 143.4 · Net income 6.6
50M100M-20M-40M200920112013201520172019202120232025
Compound annual growth
+9.3%
+8.1%
+7.4%
+7.7%
+616.7%
−17.5%
+9.1%
−17.3%
+10.0%
+21.8%
+49.3%
+39.4%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at +8.1% a year over five years.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability
5 cents
of every revenue dollar became profit
Operating margin Net margin
FY2025 · Operating 8.3% · Net 4.6%
-100%-200%200920112013201520172019202120232025
ROE
FY2025 · ROE 11.5%
20%40%-20%-40%-60%200920112013201520172019202120232025

Each USD of equity produced 12 cents of profit this year.

Cash & shareholders
USD 9.9M
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF 23.8
8M16M200920112013201520172019202120232025
Net buybacks $M Dividends $M
FY2025 · Dividends — · Net buybacks 9.9
4M8M20102012201420162019202120232025

USD 9.9M in buybacks — 149% of the year's profit, so the payout drew on cash built up earlier.

Total assetsUSD 100.6M
EquityUSD 57.3M
CashUSD 3.2M
Gross debtUSD 19.6M
Net debtUSD 16.4M
Current ratio1.80×

Net debt stands at 29% of equity.

The 17-year record
17 fiscal years
Every figure from documents filed with the SEC · USD
row low → row highnegative
Metric 20252024202320222021202020192018201720162015201420132012201120102009
Revenue $B0.10.10.10.10.10.10.10.10.00.10.10.10.10.10.10.00.0
Operating income $B0.00.00.00.00.00.00.00.0−0.00.00.00.00.00.0−0.1−0.00.0
EBITDA $B0.00.00.00.00.00.00.00.00.00.00.00.00.00.0−0.10.00.0
Income tax $B0.00.00.00.0−0.0−0.00.00.00.0−0.00.00.00.0−0.0−0.0−0.00.0
Net income $B0.00.00.00.00.00.00.0−0.0−0.0−0.00.00.00.0−0.0−0.0−0.00.0
Free cash flow $B0.00.00.00.00.00.00.00.00.00.00.00.00.0−0.0−0.00.00.0
EPS, diluted $0.310.110.040.000.060.800.07−0.05−0.91−0.010.120.150.08−0.07−2.16−0.090.04
Dividend / sh $·················
Payout %·················
ROE %11.54.31.70.03.254.96.4−4.3−50.7−0.45.87.54.0−3.7−72.5−2.21.0
Shares out B0.020.020.020.020.020.020.020.020.020.020.020.020.020.020.020.02·

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Provenance
Company facts, as filed
How we verify · 0 failures · 8 divergences in 81 reconciliationsAUDITED

Reconciled in 9 of 19 fiscal years. 8 of those reconciliations are divergences — the figures exist but don't fit the formula this check expects; that isn't the same as an error. 14 checks could not be computed.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures8 divergent
ActivitySurgical & Medical Instruments & Apparatus
Listed onNYSE
Incorporated inDelaware
Fiscal year endsDecember 31
SEC categorysmaller reporting company
Data on record since2009

Share this section

Download image